Abiopharma

ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET

Lillys baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial

Lillys EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis

New Form 6-K - Nanobiotix S.A. Filed: 2025-10-24 AccNo: 0001171843-25-006647 Size: 15 KB

CoyaTherapeutics - Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

New Form 6-K - Sanofi Filed: 2025-10-24 AccNo: 0001121404-25-000026 Size: 1 MB

Halper Sadeh LLC Encourages Twist Bioscience Corporation Shareholders to Contact the Firm to Discuss Their Rights

New Form 6-K - GSK plc Filed: 2025-10-24 AccNo: 0001654954-25-012159 Size: 2 MB

(99% Neutral) TANGO THERAPEUTICS, INC. (TNGX) Announces Business Combination

New Form 6-K/A - I-Mab Filed: 2025-10-24 AccNo: 0001193125-25-249298 Size: 2 MB

New Form 424B5 - Tango Therapeutics, Inc. Filed: 2025-10-24 AccNo: 0001193125-25-249286 Size: 636 KB

New Form 6-K - Sanofi Filed: 2025-10-24 AccNo: 0001193125-25-249279 Size: 176 KB

Employee Stock Option/ Share Scheme: NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) - OTHER ISSUE OF SECURITIES

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016